Abstract
Access to effective antimalarial therapy has increased dramatically. As malaria-endemic countries begin to use artemisinin-based combination therapy (ACT) to treat malaria, detecting the emergence and spread of resistance has become more complicated but also more urgent. Clinical efficacy studies may not be sensitive enough to detect the failure of a single component of combination therapy while standardized criteria for in vitro resistance and validated molecular markers are not yet available to many currently deployed drugs. This review discusses the challenges to various methods to monitor antimalarial drug resistance and proposes an integrated approach to the rapid detection and characterization of resistance to ACTs should it arise.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
World Health Organization: Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: World Health Organization; 2003.
Stepniewska K, Taylor WR, Mayxay M, et al.: In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 2004, 48:4271–4280.
World Health Organization: Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. Geneva, Switzerland: World Health Organization; 2008.
Hoffman SL, Masbar S, Hussein PR, et al.: Absence of malaria mortality in villagers with chloroquine-resistant Plasmodium falciparum treated with chloroquine. Trans R Soc Trop Med Hyg 1984, 78:175–178.
Djimde AA, Doumbo OK, Traore O, et al.: Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003, 69:558–563.
Laufer MK, van Oosterhout JJ, Thesing PC, et al.: Malaria treatment efficacy among people living with HIV: the role of host and parasite factors. Am J Trop Med Hyg 2007, 77:627–632.
Greenhouse B, Slater M, Njama-Meya D, et al.: Decreasing efficacy of antimalarial combination therapy in Uganda explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis, in press.
Dzinjalamala FK, MacHeso A, Kublin JG, et al.: Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2005, 72:267–272.
Laufer MK, Plowe CV: The interaction between HIV and malaria in Africa. Curr Infect Dis Rep 2007, 9:47–54.
Laufer MK, van Oosterhout JJ, Thesing PC, et al.: Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 2006, 193:872–878.
Price RN, Uhlemann AC, van Vugt M, et al.: Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006, 42:1570–1577.
White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemetherlumefantrine. Clin Pharmacokinet 1999, 37:105–125.
White NJ, Stepniewska K, Barnes K, et al.: Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol 2008, 24:159–163.
World Health Organization: Containment of Malaria Multi-Drug Resistance on the Cambodia-Thailand Border. Geneva, Switzerland: World Health Organization; 2007. Report no. SEA-MAL-246.
Noedl H, Thap LC, Se Y, et al.: Artemisinin resistance in Cambodia? [abstract 934]. Presented at the Annual Meeting of the American Society of Tropical Medicine. Philadelphia, PA; November 8, 2007.
Ittarat W, Pickard AL, Rattanasinganchan P, et al.: Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg 2003, 68:147–152.
Laufer MK, Djimde AA, Plowe CV: Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am J Trop Med Hyg 2007, 77(6 Suupl):160–169.
Kaddouri H, Djimde A, Dama S, et al.: Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol 2008, 38:791–798.
Bacon DJ, Latour C, Lucas C, et al.: Comparison of a SYBR green I-based assay with a histidine-rich protein II enzymelinked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother 2007, 51:1172–1178.
Rason MA, Randriantsoa T, Andrianantenaina H, et al.: Performance and reliability of the SYBR green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg 2008, 102:346–351.
Basco LK: Molecular epidemiology of malaria in Cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Am J Trop Med Hyg 2004, 70:474–480.
Bacon DJ, Jambou R, Fandeur T, et al.: World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J 2007, 6:120.
Ekland EH, Fidock DA: In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol 2008, 38:743–747.
Bzik DJ, Li WB, Horii T, Inselburg J: Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci U S A 1987, 84:8360–8364.
Foote SJ, Thompson JK, Cowman AF, Kemp DJ: Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 1989, 57:921–930.
Brooks DR, Wang P, Read M, et al.: Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 1994, 224:397–405.
Peterson DS, Walliker D, Wellems TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 1988, 85:9114–9118.
Wellems TE, Walker-Jonah A, Panton LJ: Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci U S A 1991, 88:3382–3386.
Fidock DA, Nomura T, Talley AK, et al.: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000, 6:861–871.
Plowe CV, Cortese JF, Djimde A, et al.: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997, 176:1590–1596.
Wang P, Lee CS, Bayoumi R, et al.: Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 1997, 89:161–177.
Djimde A, Doumbo OK, Cortese JF, et al.: A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001, 344:257–263.
Kublin JG, Dzinjalamala FK, Kamwendo DD, et al.: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002, 185:380–388.
Djimde A, Doumbo OK, Steketee RW, Plowe CV: Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001, 358:890–891.
Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al.: Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424:957–961.
Jambou R, Legrand E, Niang M, et al.: Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960–1963.
Zhang G, Guan Y, Zheng B, et al.: No PfATPase6 S769N mutation found in Plasmodium falciparum isolates from China. Malar J 2008, 7:122.
Mugittu K, Genton B, Mshinda H, Beck HP: Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malar J 2006, 5:126.
Ferreira ID, Lopes D, Martinelli A, et al.: In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from Sao Tome and Principe. Trop Med Int Health 2007, 12:353–362.
Price RN, Uhlemann AC, Brockman A, et al.: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438–447.
Sidhu AB, Uhlemann AC, Valderramos SG, et al.: Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 2006, 194:528–535.
Ferreira ID, Rosario VE, Cravo PV: Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in Plasmodium falciparum. Malar J 2006, 5:1.
Nyunt MM, Plowe CV: Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther 2007, 82:601–605.
Stepniewska K, White NJ: Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008, 52:1589–1596.
Sibley CH, Barnes KI, Watkins WM, Plowe CV: A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol 2008, 24:43–48.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laufer, M.K. Monitoring antimalarial drug efficacy: Current challenges. Curr Infect Dis Rep 11, 59–65 (2009). https://doi.org/10.1007/s11908-009-0009-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11908-009-0009-3